

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)

Friday, March 4, 2016

**142nd Meeting of the Vaccines and Related Biological Products
Advisory Committee**
FDA White Oak Campus, Building 31, Great Room (Room 1503)
Silver Spring, MD 20993

Live Webcast: <https://collaboration.fda.gov/vrbpac030416/>.

DRAFT AGENDA

Time	Presentation/Presenter
8: 30 A.M.	Call to Order and Opening Remarks Introduction of Committee Ruth Lynfield, M.D. Acting Chair, VRBPAC
	Conflict of Interest Statement Sujata Vijh, Ph.D. Designated Federal Officer, VRBPAC, FDA
	Topic: Strain Selection for the Influenza Virus Vaccines for the 2016-2017 Influenza Season
8:45a.m.	Introduction Anissa Cheung, M.Sc. Regulatory Coordinator Division of Viral Products Office of Vaccines Research and Review CBER/FDA
8:55 a.m.	U.S. Surveillance Lisa Grohskopf, M. D., M. P. H. CAPT. USPHS Associate Chief for Policy & Liaison Activities, Epidemiology & Prevention Branch, Influenza Division Centers for Disease Control and Prevention
9:20 a.m.	World Surveillance/ Virus Characterization Jacqueline Katz, Ph.D. Deputy Director (Acting), Influenza Division Director, WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza, Center for Immunization & Influenza, Center for Immunization & Respiratory Diseases Centers for Disease Control and Prevention
10:20 a.m.	BREAK

Time	Presentation/Presenter
10:35 a.m.	DoD Vaccine Effectiveness Report Michael Cooper, Ph.D. CAPT, PHS Leader, Respiratory Pillar Activities Division of Global Emerging Infection Surveillance Armed Forces Health Surveillance Center
10:55 a.m.	Vaccine Responses Zhiping Ye, M.D., Ph.D. Senior Investigator Division of Viral Products Office of Vaccines Research and Review CBER/FDA
11:15 a.m.	Candidate Vaccine Strains & Potency Reagents Manju Joshi, Ph.D. Lead Biologist Division of Biological Standards & Quality Office of Compliance and Biologics Quality CBER/FDA
11:35 a.m.	Comments from Manufacturers Matthew Downham, Ph.D. Associate Director, Biopharmaceutical Development AstraZeneca
11:55 a.m.	LUNCH
12:50 p.m.	Open Public Hearing
1:50 p.m.	Committee Discussion, Voting and Recommendations
3:00 p.m.	Adjournment